Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin dose-level study in relapsed or refractory B-cell acute lymphoblastic leukemia at high risk of veno-occlusive disease
2018-001557-27Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Pfizer. Primary endpoint: Rate of veno-occlusive disease. Started Jan 2019; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2018-001557-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001557-27.